← Back to patent-cliff list
INM-755
Tier C — Watch / tradeINM-755
InMed Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CB
Indications (approved)：Myalgia, 紧张型头痛, 面部疼痛, Headache, 大疱性表皮松解症, 单纯性大疱性表皮松解, 交界型大疱性表皮松解, 营养不良性大疱性表皮松解
Regional status
US
-
EU
Phase III
2025-04-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of INM-755?
Approved indications include: Myalgia, 紧张型头痛, 面部疼痛, Headache, 大疱性表皮松解症, 单纯性大疱性表皮松解, 交界型大疱性表皮松解, 营养不良性大疱性表皮松解.
When does the INM-755 patent expire?
No public expiry year is available for INM-755 yet; this page updates once verified.
How do I get a quote for INM-755 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30